Pfizer vaccine appears to be very effective against South African strain
DECRYPTION – The US-German alliance has also reported good results regarding the length of protection of its vaccine.
As AstraZeneca’s vaccine bogs down with possible rare side effects, the one developed by Pfizer and BioNTech is collecting the good news. Last Thursday, the US-German alliance indeed announced that their messenger RNA vaccine is “Highly efficient” (91.3%) for at least six months after the second dose, based on as yet unpublished data from 12,000 participants. Until now, the duration of protection was unknown, for lack of sufficient perspective. The same goes for other authorized vaccines.
A few days earlier, the two laboratories had affirmed that their vaccine is 100% effective in adolescents aged 12 to 15 years, according to the results of a phase 3 clinical trial conducted on more than 2,200 young people. A very encouraging result: although the vaccination of the youngest has not been a priority so far, it could well be put on the agenda in the coming months. Hence the interest in insuring
This article is for subscribers only. You have 70% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
Already subscribed? Log in